TheraRadar
← Back
Data updated: Mar 29, 2026

JIANGSU HANSOH PHARM

OncologyMetabolicInfectious Disease
Generics

JIANGSU HANSOH PHARM is a generic drug manufacturer focused on Oncology, Metabolic, Infectious Disease.

2012
Since
11
Drugs
-
Trials
107
Approved (2yr)

Key Drugs

No active drugs

Top Drug Revenues Pro

Loading...

Revenue Over Time Pro

Loading...

Recent Activity

MICAFUNGIN SODIUM 2026-02-24
OLANZAPINE 2026-02-09
Labeling
OLANZAPINE 2026-02-09
Labeling
OLANZAPINE 2026-01-23
OLANZAPINE 2026-01-22
Labeling
MICAFUNGIN SODIUM 2026-01-21
OLANZAPINE 2026-01-06
Labeling
OLANZAPINE 2026-01-06
Labeling
SEC Filings Pro
Loading...

Therapeutic Areas

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Oncology 60%
4 drugs Phase 3: 3 Phase 2: 1 Phase 1: 17
Metabolic 20%
0 drugs Phase 3: 3 Phase 2: 2 Phase 1: 2
Infectious Disease 12%
1 drugs Phase 3: 1 Phase 1: 1
Immunology 8%
0 drugs Phase 3: 1 Phase 1: 3
Gastroenterology 1%
0 drugs Phase 1: 1

Pipeline Forecast

Loading...

Upcoming Trial Milestones Pro

Loading...

Patent Cliff Pro

Loading...

Competitors by Therapeutic Area

Pfizer big-pharma
Oncology, Infectious Disease, Immunology, Gastroenterology
Merck big-pharma
Oncology, Infectious Disease, Immunology, Metabolic
Johnson & Johnson big-pharma
Oncology, Immunology, Infectious Disease, Metabolic
Sanofi big-pharma
Metabolic, Oncology, Infectious Disease, Immunology
Bristol-Myers Squibb big-pharma
Oncology, Immunology, Gastroenterology, Infectious Disease